Drug Trial Radar · NCT07326995
Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 24, 2025
Primary completion
Feb 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhalation Aerosol in patients with bronchial asthma.
Conditions
- Bronchial Asthma
Interventions
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 daysDrug
PA9159 of 60 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 daysDrug
PA9159 of 120 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
PA9159 Metered-Dose Inhaler, 240 μg per day for 28 daysDrug
PA9159 of 240 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
Placebo Metered-Dose Inhaler without PA9159, Twice daily for 28 daysDrug
Placebo is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation the change in morning pre-dose forced expiratory volume in one second (FEV1) from baseline to week 4 of treatment.Time frame: From pre-dose until 28 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.